Contraception Oral Contraceptives

Association of hormonal contraceptive use with reduced levels of depressive symptoms: a national study of sexually active women in the United States

Keyes KM, Cheslack-Postava K, Westhoff C, Heim CM, Haloossim M, Walsh K, Koenen K

Published November 2013 American journal of epidemiology, 178(9), 1378-1388
DOI 10.1093/aje/kwt188 PMID 24043440 PMC PMC3888252

Abstract

An estimated 80% of sexually active young women in the United States use hormonal contraceptives during their reproductive years. Associations between hormonal contraceptive use and mood disturbances remain understudied, despite the hypothesis that estrogen and progesterone play a role in mood problems. In this study, we used data from 6,654 sexually active nonpregnant women across 4 waves of the National Longitudinal Study of Adolescent Health (1994-2008), focusing on women aged 25-34 years. Women were asked about hormonal contraceptive use in the context of a current sexual partnership; thus, contraceptive users were compared with other sexually active women who were using either nonhormonal contraception or no contraception. Depressive symptoms were assessed with the Center for Epidemiologic Studies Depression Scale. At ages 25-34 years, hormonal contraceptive users had lower mean levels of concurrent depressive symptoms (β = -1.04, 95% confidence interval: -1.73, -0.35) and were less likely to report a past-year suicide attempt (odds ratio = 0.37, 95% confidence interval: 0.14, 0.95) than women using low-efficacy contraception or no contraception, in models adjusted for propensity scores for hormonal contraceptive use. Longitudinal analyses indicated that associations between hormonal contraception and depressive symptoms were stable. Hormonal contraception may reduce levels of depressive symptoms among young women. Systematic investigation of exogenous hormones as a potential preventive factor in psychiatric epidemiology is warranted.

Topics

By this author

Related research

Contraception › Oral Contraceptives › Metabolic Effects · Therapeutics › Hormonal Agents › Estrogen Preparations
Katherine M Keyes, Keely Cheslack-Postava, Carolyn Westhoff, Christine M Heim, Michelle Haloossim, Kate Walsh, Karestan Koenen
Kathy Keyes, Kate Keyes, Katie Keyes, K Keyes, K Cheslack-Postava, C Westhoff, Chris Heim, C Heim, M Haloossim, Catherine Walsh, Katherine Walsh, Kathryn Walsh, K Walsh, K Koenen
PMID 24043440 24043440 DOI 10.1093/aje/kwt188 10.1093/aje/kwt188 Keyes et al. 2013, Keyes 2013